A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Oncologist - United States
doi 10.1634/theoncologist.2015-0105
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Phase II Trial of Sorafenib in Advanced Thyroid Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2008English

Phase I/Ii Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers

Oncologist
Cancer ResearchMedicineOncology
2015English

Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

Age-Stratified Phase I Trial of a Combination of Bortezomib, Gemcitabine, and Liposomal Doxorubicin in Patients With Advanced Malignancies

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2011English

Sorafenib in Advanced Melanoma: A Critical Role for Pharmacokinetics?

British Journal of Cancer
Cancer ResearchOncology
2012English

A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers

Clinical Colorectal Cancer
OncologyGastroenterology
2014English

Phase II Trial of Karenitecin in Patients With Malignant Melanoma: Clinical and Translational Study

Clinical Cancer Research
Cancer ResearchOncology
2005English

Randomized, Phase II Trial of Sequential Hepatic Arterial Infusion Chemotherapy and Sorafenib Versus Sorafenib Alone as Initial Therapy for Advanced Hepatocellular Carcinoma: SCOOP-2 Trial

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

A Phase I Trial of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL0916)

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy